Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: A meta-analysis

American Journal of Medicine

Volumn 112, Issue 5, 2002, Pages 406-411

  Lyman, Gary H ^a,b   Kuderer, Nicole M ^a   Djulbegovic, Benjamin ^c  

^a ALBANY MEDICAL COLLEGE   (United States)

^b STATE UNIVERSITY OF NEW YORK   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CISPLATIN; CLOTRIMAZOLE; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; IFOSFAMIDE; KETOCONAZOLE; MESNA; METHOTREXATE; MITOXANTRONE; PREDNISOLONE; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINCRISTINE; VINDESINE;

ARTICLE; BONE PAIN; CANCER CHEMOTHERAPY; CANCER MORTALITY; CLINICAL TRIAL; DATA BASE; DOSE RESPONSE; DRUG EFFICACY; FEBRILE NEUTROPENIA; HUMAN; INFECTION; INFORMATION PROCESSING; LYMPHOMA; META ANALYSIS; PRIORITY JOURNAL; RISK FACTOR; SOLID TUMOR; TREATMENT OUTCOME;

EID: 0036532256     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(02)01036-7     Document Type: Review

References (24)

1. Effect of granulocyte colony stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional cell carcinoma of the urothelium
2. Treatment of chemotherapy-induced neutropenia by subcutaneously administered granulocyte colony-stimulating factor with optimization of dose and duration of therapy
3. Filgrastim (r-metHuG-CSF): The first ten years
4. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer
5. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy
6. Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: A randomized controlled trial
7. Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer
8. Efficacy of lenograstim on hematologic tolerance to MAID chemotherapy in patients with advanced soft tissue sarcoma and consequences on treatment dose-intensity
9. Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's lymphoma
10. Placebo-controlled phase III study of lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) in aggressive non-Hodgkin's lymphoma: Factors influencing chemotherapy administration
11. Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy
12. Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy
13. The impact of therapy with filgrastim (recombinant colony-stimulating factor) on health care costs associated with cancer chemotherapy
14. A cost analysis of hematopoietic colony-stimulating factors
15. The economics of febrile neutropenia: Implications for the use of the colony-stimulating factors
16. Economic analysis of prophylactic G-CSF after mini-BEAM salvage chemotherapy for Hodgkin's and non-Hodgkin's lymphoma
17. Cost-benefit of granulocyte-stimulating factor administration in older patients with non-Hodgkin's lymphoma treated with combination chemotherapy
18. Cost-minimization analysis of prophylactic granulocyte colony-stimulating factor after induction chemotherapy in children with non-Hodgkin's lymphoma
19. Update of the economic analyses of the use of the colony-stimulating factors
20. A novel approach to maintain planned dose chemotherapy on time: A decision-making tool to improve patient care
21. 2000 Update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines
22. Assessing the quality of randomized controlled trials: An annotated bibliography of scales and checklists
23. Statistical methods in cancer research. Volume II - The design and analysis of cohort studies
24. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples